Compare Stocks

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKU Akumin		$0.18	$0.12 ▼ $1.90	$26.32M	-0.72	1.38 million shs	8.54 million shs
ONC Oncolytics Biotech	C$1.43 -0.7%	C$1.44	C$1.20 ▼ C$4.49	C$107.85M	1.49	80,073 shs	23,151 shs
PTN Palatin Technologies	$1.88 -1.1%	$0.00	$1.43 ▼ $5.65	$30.34M	0.93	649,955 shs	180,638 shs

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKU Akumin	0.00%	0.00%	0.00%	0.00%	-52.67%
ONC Oncolytics Biotech	-0.69%	-10.06%	+2.88%	-11.73%	-7.74%
PTN Palatin Technologies	0.00%	-2.67%	+18.18%	-54.27%	-31.32%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKU Akumin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONC Oncolytics Biotech	0.5953 of 5 stars	3.5	0.0	0.0	0.0	1.1	0.0	0.0
PTN Palatin Technologies	1.9684 of 5 stars	3.5	2.0	0.0	0.0	2.6	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKU Akumin	1.50	Reduce	$0.25	∞ Upside
ONC Oncolytics Biotech	3.00	Buy	C$6.00	319.58% Upside
PTN Palatin Technologies	3.00	Buy	$17.00	804.26% Upside

Current Analyst Ratings

Latest PTN, YGEN, AKU, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/4/2024	ONC Oncolytics Biotech	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	C$3.00
2/28/2024	PTN Palatin Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$70.00 ➝ $17.00
2/15/2024	PTN Palatin Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKU Akumin	$749.63M	0.00	N/A	N/A	$1.24 per share	0.00
ONC Oncolytics Biotech	N/A	N/A	C$0.34 per share	4.22	C$0.37 per share	N/A
PTN Palatin Technologies	$4.85M	6.26	N/A	N/A	$0.01 per share	188.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKU Akumin	-$156.76M	-$2.52	N/A	N/A	N/A	-30.56%	-167.86%	-7.81%	N/A
ONC Oncolytics Biotech	-C$27.75M	-C$0.41	N/A	∞	N/A	N/A	-102.66%	-55.47%	5/3/2024 (Estimated)
PTN Palatin Technologies	-$27.54M	-$2.58	N/A	N/A	N/A	-445.12%	-583.06%	-184.90%	5/14/2024 (Estimated)

Latest PTN, YGEN, AKU, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/7/2024	Q4 2023	ONC Oncolytics Biotech	-C$0.15	-C$0.05	+C$0.10	-C$0.05	N/A	N/A
2/14/2024	Q2 24	PTN Palatin Technologies	-$0.20	-$0.56	-$0.36	-$0.56	$2.28 million	$2.03 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKU Akumin	N/A	N/A	N/A	N/A	N/A
ONC Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
PTN Palatin Technologies	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKU Akumin	17.02	0.99	0.99
ONC Oncolytics Biotech	1.54	9.01	8.86
PTN Palatin Technologies	N/A	1.09	1.09

Ownership

Institutional Ownership

Company	Institutional Ownership
AKU Akumin	36.10%
ONC Oncolytics Biotech	6.98%
PTN Palatin Technologies	11.50%

Insider Ownership

Company	Insider Ownership
AKU Akumin	20.51%
ONC Oncolytics Biotech	6.24%
PTN Palatin Technologies	7.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AKU Akumin	3,631	91.17 million	72.47 million	Not Optionable
ONC Oncolytics Biotech	29	75.42 million	N/A	Not Optionable
PTN Palatin Technologies	34	16.14 million	14.89 million	Not Optionable

PTN, YGEN, AKU, and ONC Headlines

Source	Headline
	Palatin Technologies (NYSEAMERICAN:PTN) Stock Price Crosses Above 200 Day Moving Average of $0.00 americanbankingnews.com - April 19 at 3:40 AM
	Palatin Technologies, Inc. (NYSEAMERICAN:PTN) Director Buys $12,720.00 in Stock americanbankingnews.com - April 14 at 5:26 AM
	Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying msn.com - April 12 at 10:36 AM
	Palatin Technologies, Inc. (NYSEAMERICAN:PTN) Director Purchases $12,720.00 in Stock insidertrades.com - April 12 at 6:56 AM
	Palatin Technologies (NYSEAMERICAN:PTN) Shares Pass Above 200-Day Moving Average of $0.00 americanbankingnews.com - April 10 at 3:22 AM
	Palatin (PTN) Up 15% on Results From Dry Eye Disease Study zacks.com - April 9 at 10:01 AM
	Palatin Technologies Shares Rise 27% After Positive Trial Results for PL9643 marketwatch.com - April 8 at 1:18 PM
	Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data finance.yahoo.com - April 8 at 1:18 PM
	Galectin Therapeutics, Titan Pharmaceuticals, Outset Medical among healthcare movers msn.com - April 8 at 10:21 AM
	Palatin stock jumps 16% on positive Phase 3 data for eye drug msn.com - April 8 at 10:12 AM
	Palatin Says Topline Results From The Phase 3 MELODY-1 Study Of PL9643 In Dry Eye Disease Positive markets.businessinsider.com - April 8 at 8:18 AM
$Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024$	Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 finance.yahoo.com - April 8 at 8:18 AM
	Palatin Technologies, Inc. (NYSEAMERICAN:PTN) Director Robert K. Deveer, Jr. Sells 11,700 Shares insidertrades.com - March 17 at 8:52 AM
	PTN Apr 2024 2.500 put finance.yahoo.com - March 15 at 10:53 PM
	PTN Apr 2024 7.500 call finance.yahoo.com - March 15 at 10:53 PM
	Palatin files to sell 1.92M shares of common stock for holders msn.com - March 14 at 7:20 PM
	Maintained Buy Rating on Palatin Technologies Amid Promising Clinical Results and Future Prospects markets.businessinsider.com - February 29 at 3:20 PM
	Palatin to tweak second PL-9643 phase III in dry eye disease bioworld.com - February 28 at 7:51 PM
	Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Palatin Technologies (PTN) and G1 Therapeutics (GTHX) markets.businessinsider.com - February 28 at 5:21 PM
	Analysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN) and Opko Health (OPK) markets.businessinsider.com - February 28 at 2:50 PM
	Palatin CEO claims ‘a positive study on its face,’ despite dry eye drug's primary endpoint miss fiercebiotech.com - February 28 at 12:20 PM
	Palatin Technologies' Disappointing Data From Dry Eye Disease Study, Stock Plummets msn.com - February 28 at 12:20 PM
	Palatin Technologies, Inc.: Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) finanznachrichten.de - February 28 at 9:49 AM
	Palatin Technologies Shares Tumble Premarket on Dry-Eye Study Results marketwatch.com - February 28 at 9:49 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Akumin

NASDAQ:AKU

Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other diagnostic and interventional radiology procedures through owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to hospitals and health systems across 48 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.

Oncolytics Biotech

TSE:ONC

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Palatin Technologies

NYSEAMERICAN:PTN

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial